News Digest / Lukas Schmidt

Author: Lukas Schmidt

02:57am, Wednesday, Aug 20, 2025
Viking Therapeutics (VKTX) plunged ~37% after Phase 2 VENTURE showed VK2735 met its primary endpoint-up to 12.2% weight loss at 13 weeks-but a 28% discontinuation rate and GI side effects spurred adoption worries; Eli Lilly (LLY) edged up.